To address neglected tropical diseases (NTDs) as matters of health, equality, and human rights, as called for by the UN.
Approach:
Resolution Adoption: The UN Human Rights Council adopted Resolution 62/21 during its 62nd session, focusing on NTDs as preventable and treatable conditions.
Integration into Health Systems: The resolution urges countries to integrate NTD prevention, early detection, diagnosis, treatment, and continuing care into primary health care and universal health coverage.
Support and Coordination: Calls for increased support from UN agencies and partners, and coordination for surveillance and prevention across borders.
Addressing Disability and Discrimination: Encourages disability-inclusive NTD programs and the involvement of affected communities in health program design.
Environmental Considerations: Highlights the impact of climate change on NTD transmission and calls for improved living conditions in affected areas.
Key Findings:
NTDs affect over 1 billion people, disproportionately impacting those in poverty and underserved communities.
The resolution emphasizes the need for accessible and quality health services without discrimination.
It calls for the protection of NTD programs during health emergencies and humanitarian crises.
Disability-inclusive approaches and addressing stigma are critical components of the response to NTDs.
The resolution links NTD transmission to broader conditions in which people live.
Interpretation:
The resolution marks a significant shift in recognizing NTDs as human rights issues, not just medical concerns.
Limitations:
The effectiveness of the resolution depends on the commitment and resources of individual countries.
The timeline for the comprehensive report may delay immediate actions needed to address NTDs.
Conclusion:
Resolution 62/21 expands the focus on NTDs beyond medical treatment to include human rights and social determinants.
More than 5,100 additional reports require further analysis as federal and state partners investigate several outbreaks and work to identify their sources.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.